VPI-PIPERACILLIN AND TAZOBACTAM FOR INJECTION 1.5 G — DIN 02452588
TAZOBACTAM (TAZOBACTAM SODIUM) : 1.5 G PIPERACILLIN (PIPERACILLIN SODIUM) : 12 G · VPI PHARMACEUTICALS INC · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: APPROVED
What is VPI-PIPERACILLIN AND TAZOBACTAM FOR INJECTION?
VPI-PIPERACILLIN AND TAZOBACTAM FOR INJECTION 1.5 G contains TAZOBACTAM (TAZOBACTAM SODIUM) : 1.5 G PIPERACILLIN (PIPERACILLIN SODIUM) : 12 G. It is listed in the Health Canada Drug Product Database under DIN 02452588, held by VPI PHARMACEUTICALS INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as approved, status dated 29-Feb-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
How much does Piperacillin And Beta-Lactamase Inhibitor cost around the world?
Piperacillin And Beta-Lactamase Inhibitor is listed on 4 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Romania publishes a max producer price; Saudi Arabia publishes a public; South Africa publishes a single exit price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 13 | 15 | SAR███.██ |
| South Africa | single exit price | 13 | 15 | ZAR███.██ |
| Romania | max producer price | 4 | 6 | RON███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
38 pack listings across 32 brand entries and 4 price bases, refreshed 03 Sep 2026. Ranges span every Piperacillin And Beta-Lactamase Inhibitor pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Piperacillin And Beta-Lactamase Inhibitor in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
15 holders have a Canadian DIN containing Piperacillin And Beta-Lactamase Inhibitor, across 52 DINs, of which 16 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SANDOZ CANADA INCORPORATED | 5 | 5 | PIPERACILLIN AND TAZOBACTAM FOR INJECTION | Sourceable in Canada |
| STERIMAX INC | 5 | 5 | PIPERACILLIN AND TAZOBACTAM FOR INJECTION | Sourceable in Canada |
| AURO PHARMA INC | 5 | 3 | PIPERACILLIN AND TAZOBACTAM FOR INJECTION | Sourceable in Canada |
| EUGIA PHARMA INC. | 5 | 3 | PIPERACILLIN AND TAZOBACTAM FOR INJECTION | Sourceable in Canada |
| VPI PHARMACEUTICALS INC | 5 | 0 | VPI-PIPERACILLIN AND TAZOBACTAM FOR INJECTION | No marketed DIN |
| APOTEX INC | 3 | 0 | PIPERACILLIN AND TAZOBACTAM FOR INJECTION | No marketed DIN |
| HIKMA CANADA LIMITED | 3 | 0 | PIPERACILLIN AND TAZOBACTAM FOR INJECTION | No marketed DIN |
| LEDERLE CYANAMID CANADA INC. | 3 | 0 | TAZOCIN PWS IV 2G PIPERACILLIN-.25G TAZOBAC., TAZOCIN PWS IV 3G PIPERACILLIN-.375G TAZOBAC, TAZOCIN PWS IV 4G PIPERACILLIN-.5G TAZOBAC. | No marketed DIN |
| MARCAN PHARMACEUTICALS INC | 3 | 0 | PIPERACILLIN AND TAZOBACTAM FOR INJECTION | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 3 | 0 | PIPERACILLIN AND TAZOBACTAM FOR INJECTION | No marketed DIN |
| PFIZER CANADA ULC | 3 | 0 | TAZOCIN | No marketed DIN |
| PHARMA STRIDES CANADA CORPORATION | 3 | 0 | PIPERACILLIN/TAZOBACTAM FOR INJECTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1.5 G |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Piperacillin And Beta-Lactamase Inhibitor |
|---|---|
| ATC code | J01CR05 |
| AHFS class | 08:12.16.16 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02452588 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2452588 |
| Brand name | VPI-PIPERACILLIN AND TAZOBACTAM FOR INJECTION |
| Generic / active ingredient | TAZOBACTAM (TAZOBACTAM SODIUM) : 1.5 G PIPERACILLIN (PIPERACILLIN SODIUM) : 12 G |
| Market authorization holder | VPI PHARMACEUTICALS INC |
| Health Canada schedule | Prescription |
| ATC code | J01CR05 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01CR |
| Current status | APPROVED |
| Status date | 29-Feb-2016 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Piperacillin And Beta-Lactamase Inhibitor in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
Check availability for VPI-PIPERACILLIN AND TAZOBACTAM FOR INJECTION
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
16 of 52 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 0.5 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | 02362635 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 2 G | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | 02402068 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 1.5 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02330547 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 3.000 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | 02362627 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 12 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | 02377748 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 2 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02299623 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 3 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02299631 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 4 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02299658 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 2.00 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | 02362619 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 3 G | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | 02402076 |
2 · Same class — other molecules in ATC J01CR
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Amoxicillin And Beta-Lactamase Inhibitor | AG-AMOXI CLAV · AG-AMOXI CLAV SUSPENSION · AMOXI-CLAV · AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION · +28 more | 59 | 28 | Yes |
| Piperacillin And Beta-Lactamase Inhibitor | JAMP-PIP/TAZ · PIPERACILLIN / TAZOBACTAM POWDER FOR INJECTION · PIPERACILLIN AND TAZOBACTAM FOR INJECTION · PIPERACILLIN/TAZOBACTAM FOR INJECTION · +5 more | 52 | 16 | Yes |
| Ticarcillin And Beta-Lactamase Inhibitor | TIMENTIN | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J01C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J01CA | Amoxicillin · Ampicillin · Ampicillin, Combinations · Bacampicillin · Piperacillin · +3 more | 201 | 47 |
| J01CF | Beta-Lactamase Resistant Penicillins · Cloxacillin · Flucloxacillin | 42 | 9 |
| J01CE | Benzathine Benzylpenicillin · Benzathine Phenoxymethylpenicillin · Benzylpenicillin · Combinations · Phenoxymethylpenicillin · +1 more | 69 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is VPI-PIPERACILLIN AND TAZOBACTAM FOR INJECTION called?
The same molecule, Piperacillin And Beta-Lactamase Inhibitor, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Pipractam | Latin | Saudi Arabia |
| Tazopip | Latin | South Africa |
| Tapranem | Latin | South Africa |
| Tazobax | Latin | South Africa |
| Tazogen | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ask about availability of VPI-PIPERACILLIN AND TAZOBACTAM FOR INJECTION
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.